OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its T…
Category: Business
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the inc…
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes. Omeros management …
Trividia Health, Inc. Announces Launch of TRUE A-G Scan™
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Trividia Health Inc. announced today the launch of the TRUE A-G Scan™. The new product was presented this past week at NACDS Annual in Palm Beach, FL. The TRUE A-G Scan is a FDA cleared non-invasive, innovative, …
GenSight Biologics annonce la présentation des résultats à 72 semaines de l’étude de Phase III REVERSE avec GS010 au Congrès 2019 de l’American Academy of Neurology (AAN)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies…
GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central …
National Seating & Mobility to Distribute Independence Drive Wheelchair Eye Control Technology
NASHVILLE, Tenn.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/acquisition?src=hash" target="_blank"gt;#acquisitionlt;/agt;–National Seating & Mobility (NSM), the leading provider of complex rehab…
Compulink Previews New User Interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019
NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink previews new user interface for its Ophthalmology SMART EHR at ASCRS-ASOA 2019.
Eyenukの糖尿病網膜症向けAIアイ・スクリーニング・システムが前向き多施設ピボタル臨床試験で卓越した性能を証明
ロサンゼルス–(BUSINESS WIRE)–（ビジネスワイヤ） — 人工知能（AI）医療技術・サービスの世界的企業で、AIアイ・スクリーニング（AI Eye Screening™）向け実臨床アプリケーションのリーダー企業のEyenuk, Inc.は本日、EyeArt®（アイアート）AIアイ・スクリーニング・システムを対象に、糖尿病網膜症（DR）の自律的検出を検証した当社のランドマーク試験としての前向き多施設ピボタル臨床試験の結果を発表しました。失明病となるDRは、罹患者が2030年までに世界…
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Tec…
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-97…
Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
STAAR Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL by Refractive Societies in Germany and Japan
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the leading refractive ophthalmic societies in…
STAAR Surgical Reports First Quarter Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended M…
Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be…
IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019 at 8:00am ET.
Eyenuks AI Eye Screening-System für diabetische Retinopathie zeigt außergewöhnliche Leistung in einer prospektiven, multizentrischen, klinischen Schlüsselstudie.
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., ein weltweit tätiges Unternehmen für Medizintechnik und medizinische Dienstleistungen im Bereich der künstlichen Intelligenz (KI, engl. Artificial Intelligence (AI)) und Marktführer bei Anwendungen für AI Eye…